News – Feb 20, 2018

Julius Clinical to coordinate worldwide study on the effects of alcohol

The health effects of moderate (no more than 2 alcoholic beverages each day) alcohol consumption is still debated. Many studies have found that adults who reported drinking alcohol in moderation tended to develop heart disease and diabetes less often than adults who drank no alcohol. However, other studies found opposite results or showed no relationship between alcohol intake and these diseases. This study hopes to definitively answer this question.

MACH15 is the Moderate Alcohol and Cardiovascular Health Trial, a worldwide clinical study. 15 indicates that the study will test a single standard serving of alcohol daily, which contains about 15 grams of alcohol. This is equivalent to one glass of beer (350 cc), wine (150 cc) or alcohol (45 cc).

Julius Clinical will be coordinating the sites located in Argentina (one of which is Instituto Cardiovascular de Buenos Aires), Denmark (University of Copenhagen), Nigeria (Center for Bioethics and Research), and Spain (Hospital Clinic de Barcelona). We will also be working closely with the sites in the United States at Harvard University, Johns Hopkins and Wake Forest University.

In addition to the worldwide site coordination (excluding the United States), Julius Clinical is also responsible for participant recruitment in The Netherlands.

What is the study?
The MACH15 study is designed to determine whether drinking one alcoholic beverage per day will decrease the chance of developing heart disease and diabetes. It is the first randomized international clinical study to ever look at the long-term effects of alcohol on heart disease and diabetes over about 6 years of follow-up among adults 50 years or older with above-average cardiovascular risk. The study will enroll 7,800 participants worldwide.

What is the question the study hopes to answer?
MACH15 is interested in the effects of one serving of alcohol (approximately 15 grams) daily, compared to no alcohol intake on:

1.     The rate of new cases of cardiovascular disease and

2.     The rate of new cases of diabetes among participants free of diabetes at baseline.

If you are interested in participating, or know someone who is, please visit the Netherlands  website (Dutch) or the global website (English).